Target intelligence / Profile preview

22-bp pseudo-palindromic I-CreI recognition site (I-CreI target site)

Target
I-CreI target site
Molecular classification
DNA sequence, Homing endonuclease recognition site, Meganuclease substrate
01

Overview

The 22-bp pseudo-palindromic genomic DNA sequence recognized by I-CreI is the specific substrate for the I-CreI homing endonuclease, a member of the LAGLIDADG family originally identified in the chloroplast of the green alga Chlamydomonas reinhardtii (Chevalier et al., 2002). This DNA sequence is characterized by a near-symmetrical structure that allows the I-CreI homodimer to bind with high affinity and specificity, inducing a double-strand break (DSB) with 4-nucleotide 3' overhangs (Prieto et al., 2007). In its natural biological context, this interaction facilitates homing, a process where the endonuclease gene is inserted into an intron-less allele via homologous recombination. In the field of biotechnology, this 22-bp sequence serves as a foundational scaffold for the development of engineered meganucleases, such as those produced by the ARCUS platform, which are redesigned to target unique sequences within the human genome for therapeutic purposes (Smith et al., 2006). These engineered variants are utilized to treat genetic disorders and chronic viral infections by disrupting deleterious genes or facilitating precise gene insertions. The primary therapeutic challenge associated with targeting these sequences is ensuring high specificity to avoid off-target cleavage, which can lead to genotoxicity or chromosomal translocations.

Other names
I-CreI recognition sequence22-bp meganuclease targetChlamydomonas reinhardtii 23S rRNA intron sitePseudo-palindromic DNA target
02

Mechanism of action

Site-specific DNA double-strand break induction followed by cellular DNA repair mechanisms (NHEJ or HDR)

03

Biological functions

DNA bindingDNA cleavageGene homingHomologous recombinationDouble-strand break induction
04

Disease associations

Genetic disorderInfectionCancer
05

Safety considerations

Off-target DNA cleavageChromosomal translocationsGenotoxicityImmunogenicity of the delivery vector or nuclease
06

Interacting drugs

I-CreI endonuclease

4 more in the full profile.

07

Biomarkers

DNA cleavage efficiencyIndel frequencyGene correction rateOff-target cleavage profile

Beyond the preview

Go deeper on 22-bp pseudo-palindromic I-CreI recognition site (I-CreI target site).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 22-bp pseudo-palindromic I-CreI recognition site (I-CreI target site).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call